Literature DB >> 15494536

Mixed xenogeneic chimerism induces donor-specific humoral and cellular immune tolerance for cardiac xenografts.

Yolonda L Colson1, Hong Xu, Yiming Huang, Suzanne T Ildstad.   

Abstract

Xenotransplantation has been suggested as a potential solution to the critical shortage of donor organs. However, success has been limited by the vigorous rejection response elicited against solid organs transplanted across species barriers. Mixed xenogeneic bone marrow chimeras resulting from the transplantation of a mixture of host and donor marrow (B10 mouse + F344 rat --> B10 mouse) results in donor-specific cross-species transplantation tolerance for subsequent nonvascularized skin and islet grafts. Furthermore, compared with fully xenogeneic chimeras (rat --> mouse), mixed xenogeneic chimeras exhibit superior immunocompetence for infectious agents in vivo and in vitro, suggesting that the immune system is intact. The ability to establish long-term humoral and cellular tolerance for primarily vascularized xenografts in vivo, in the setting of both recipient and donor Ig and effector cell production, has not previously been characterized. Mixed xenogeneic chimeras exhibit donor-specific humoral tolerance as evident by the absence of anti-donor Ab and Ab-dependent donor-specific cytotoxicity in vitro and intravascular IgM deposition within donor-strain (F344) cardiac xenografts in vivo. F344 cardiac xenografts are accepted (median > or =180 days) without clinical or histologic evidence of rejection, suggesting cellular tolerance. In contrast, MHC-disparate third-party mouse (B10.BR) and rat (ACI or WF) grafts are rejected (median of 23 and 41 days, respectively) in association with extensive mononuclear cell infiltration and vascular deposits of mouse IgM. These results demonstrate that mixed xenogeneic chimerism establishes donor-specific humoral and cellular tolerance and permits the successful transplantation of even primarily vascularized xenografts in the setting of intact Ab production.

Entities:  

Mesh:

Year:  2004        PMID: 15494536     DOI: 10.4049/jimmunol.173.9.5827

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Past, present, and future prospects for inducing donor-specific transplantation tolerance for composite tissue allotransplantation.

Authors:  Larry D Bozulic; Warren C Breidenbach; Suzanne T Ildstad
Journal:  Semin Plast Surg       Date:  2007-11       Impact factor: 2.314

2.  Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients.

Authors:  Hong Xu; Paula M Chilton; Michael K Tanner; Yiming Huang; Carrie L Schanie; Mariano Dy-Liacco; Jun Yan; Suzanne T Ildstad
Journal:  Blood       Date:  2006-08-03       Impact factor: 22.113

3.  Evidence that FoxP3+ regulatory T cells may play a role in promoting long-term acceptance of composite tissue allotransplants.

Authors:  Larry D Bozulic; Yujie Wen; Hong Xu; Suzanne T Ildstad
Journal:  Transplantation       Date:  2011-04-27       Impact factor: 4.939

4.  Leukocyte iNOS is required for inflammation and pathological remodeling in ischemic heart failure.

Authors:  Justin R Kingery; Tariq Hamid; Robert K Lewis; Mohamed Ameen Ismahil; Shyam S Bansal; Gregg Rokosh; Tim M Townes; Suzanne T Ildstad; Steven P Jones; Sumanth D Prabhu
Journal:  Basic Res Cardiol       Date:  2017-02-25       Impact factor: 17.165

5.  Hematopoietic cell transplantation provides an immune-tolerant platform for myoblast transplantation in dystrophic dogs.

Authors:  Maura H Parker; Christian Kuhr; Stephen J Tapscott; Rainer Storb
Journal:  Mol Ther       Date:  2008-05-27       Impact factor: 11.454

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.